PharmaJet Archives - Medical Design Sourcing

PharmaJet wins NIH grant to evaluate needle-free delivery of HPV immunization

The Tropis needle-free injection system. [Image from PharmaJet]PharmaJet announced today that it received a grant worth $800,000-plus from the NIH to evaluate its needle-free injection system.

Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study compares PharmaJet’s Tropis intradermal, needle-free injection system against traditional needle and syringe intramuscular administration.

According to a news release, the study will be performed in collaboration with Padjadjaran University (UNPAD) in Indonesia. PharmaJet expects the study to recruit approximately 900 girls aged nine to 14 years old in early 2023. This follows PharmaJet’s preliminary studies evaluating intradermal delivery for HPV vaccines.

Get the full story at our sister s…

6 drug delivery innovations you need to know

From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops.

Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies.

More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some updates on some of those technologies, plus introductions to others, here are some more impressive developments you should keep an eye on:

1. Needle-free delivery

Vaccines have become a major talking point over the past couple of years amid the COVID-19 pandemic and a number of companies are working on ways to deliver them, as well as other forms of medication, through different avenues.

A major speed bump in vaccine hesitancy can be fear of needles, so the introduction of needle-free drug delivery could make big waves in the space.

Two companies pushing forward with …

PharmaJet partner touts interim safety results for needle-free COVID-19 vaccine

[Image from PharmaJet]

PharmaJet announced today that its partner, Technovalia, reported positive interim safety results from a needle-free COVID-19 vaccine trial.

Golden, Colorado-based PharmaJet’s needle-free injection systems are being studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. Enrollment for the trial began in June 2021.